Seeing Is Believing
HRMY is currently covered by 8 analysts with an average price target of $47.23. This is a potential upside of $12.95 (37.78%) from yesterday's end of day stock price of $34.28.
Harmony Biosciences Holdings's activity chart (see below) currently has 36 price targets and 79 ratings on display. The stock rating distribution of HRMY is 88.68% BUY, 5.66% HOLD and 5.66% SELL.
Analysts average stock forecasts to be materialized ratio is 44.22% with an average time for these price targets to be met of 99.11 days.
Highest price target for HRMY is $59, Lowest price target is $28, average price target is $47.23.
Most recent stock forecast was given by AMI FADIA from NEEDHAM on 30-Oct-2024. First documented stock forecast 11-Sep-2020.
12/5/00 3 for 1
Currently out of the existing stock ratings of HRMY, 47 are a BUY (88.68%), 3 are a HOLD (5.66%), 3 are a SELL (5.66%).
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$52
$19.61 (60.54%)
$52
1 months 20 days ago
(30-Oct-2024)
3/24 (12.5%)
$18.2 (53.85%)
332
Buy
$59
$26.61 (82.15%)
$69
1 months 20 days ago
(30-Oct-2024)
1/6 (16.67%)
$25.2 (74.56%)
219
Buy
$58
$25.61 (79.07%)
$49
1 months 20 days ago
(30-Oct-2024)
0/7 (0%)
$24.2 (71.60%)
Buy
$52
$19.61 (60.54%)
$40
2 months 10 days ago
(10-Oct-2024)
9/19 (47.37%)
$17.19 (49.38%)
118
Buy
$40
$7.61 (23.49%)
$27
2 months 10 days ago
(10-Oct-2024)
5/7 (71.43%)
$5.19 (14.91%)
111
What is HRMY (Harmony Biosciences Holdings) average time for price targets to be met?
Which analyst has the current highest performing score on HRMY (Harmony Biosciences Holdings) with a proven track record?
Which analyst has the current lower performing score on HRMY (Harmony Biosciences Holdings) with a proven track record?
Which analyst has the most public recommendations on HRMY (Harmony Biosciences Holdings)?
Which analyst is the currently most bullish on HRMY (Harmony Biosciences Holdings)?
Which analyst is the currently most reserved on HRMY (Harmony Biosciences Holdings)?